Menstrual timing of breast cancer surgery

American Journal of Surgery

Volumn 175, Issue 3, 1998, Pages 245-261

  Hagen, Andreas A ^a   Hrushesky, William J M ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CHRONOBIOLOGY; FEMALE; FERTILITY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK MANAGEMENT; SURGICAL RISK;

EID: 0032033080     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00294-8     Document Type: Review

References (107)

1. Cooper A. In: Lee A, ed. Practice and Principles of Surgery. London: E. Cox, St. Thomas's St., Southwark, 1836.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma suggestions for a new method of treatment with illustrative cases . Lancet. ii:1896;104-107.
3. Ratajczak HV, Sothern RB, Hrushesky WJM. Estrous influence on surgical cure of a mouse breast cancer. J Exp Med. 168:1988;73-83.
4. Butcher RL, Collins WE, Fugo NW. Plasma concentrations of LH, FSH, prolactin, progesterone and estradiol-17b throughout the 4-day estrous cycle of the rat. Endocrinology. 94:1974;1704-1708.
5. Hrushesky WJM, Bluming AZ, Gruber SA, Sothern RB. Menstrual influence on surgical cure of breast cancer. Lancet. ii:1989;949-952.
6. Potten C, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer. 58:1988;163-170.
7. Vogel P, Georgiade NG, Fetter BF, et al. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 104:1981;23-24.
8. Axelrod D, Menendez-Botet C, Kinne D, Osborne M. Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menses. Cancer Invest. 6:(1):1988;7-14.
9. Silva J, Cox E, Leight G. Effects of menstrual cycle on estrogen receptor levels in human breast cancer. Proc ASCO. 1983;abstract C-31.
10. Anderson T. Mitotic activity in breast. J Obstet Gynecol. 4:1984;S114-S118.
11. Hrushesky W. Mammography and the menstrual cycle. Int J Cancer. 59:1994;151.
12. Badwe RA, Gregory WM, Chaudary WM, et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 337:1991;1261-1264.
13. Senie R, Rosen P, Rhodes P, Lesser M. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med. 115:1991;337-342.
14. Spratt J, Zirnheld J, Yancey J. Breast cancer detection demonstration project data can determine whether the prognosis of breast cancer is affected by the time of surgery during the menstrual cycle. J Surg Oncol. 53:1993;4-9.
15. Saad Z, Bramwell J, Girotti M, et al. Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg. 81:1994;217-220.
16. Veronesi U, Luini A, Mariani L, et al. Effect of menstrual phase of surgical treatment of breast cancer. Lancet. 343:1994;1545-1547.
17. Badwe R, Wang D, Gregory W. Serum progesterone at the time of surgery and survival in woman with premenopausal operable breast cancer. Eur J Cancer. 30A:1994;445-448.
18. Ville V, Briere M, Lasry S, et al. Timing of surgery in breast cancer. Lancet. 337:1991;1604-1605.
19. von Minckwitz G, Kaufmann M, Dobberstein S, et al. Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenopausal breast cancer patients. The Breast. 4:1995;29-32.
20. Meyer K. Season and cycle: variation in presentation and response to therapy in premenopausal breast cancer. Proceedings of the 77th Annual Clinical Congress, October 21-24, Chicago, Ill, 1991.
21. Marques L, Franco E. Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer. Int J Cancer. 53:1993;707-708.
22. Stonelake P, Powell J, Dunn J. Influence of timing of surgery during menstrual cycle on survival of premenopausal woman with operable breast cancer. The Breast. 4:1995;19-24.
23. Sainsbury R, Jones M, Parker D. Timing of surgery for breast cancer and menstrual cycle. Lancet. 338:1991;391-392.
24. Levine M, Myles J, Shepherd N. Optimal timing of breast cancer surgery within the menstrual cycle: results from a prospective trial. Philadelphia, Penn: Proc ASCO 1996;99. Abstract #61.
25. Goldhirsch A, Gelber R, Forbes J. Timing breast cancer surgery. Lancet. 338:1991;691-692.
26. Goldhirsch A, Gelber R, Castiglione M, et al. Menstrual cycle and timing of breast cancer surgery in premenopausal node-positive breast cancer results of the International Breast Cancer Study Group (IBSCSG) Trial VI . Ann Oncol. 8:1997;751-756.
27. Powles TJ, Jones AL, Ashley S, Tidy A. Menstrual effect on surgical cure of breast cancer. Lancet. ii:1989;1343-1344.
28. Powles TJ, Ashley SE, Nash AG, et al. Timing of surgery in breast cancer. Lancet. 337:1991;164.
29. Ville V, Lasry S, Spyratos F. Menstrual status and breast cancer surgery. Breast Cancer Res Treat. 16:1990;119-121.
30. Rageth J, Wyss P, Unger C. Timing of breast cancer surgery within the menstrual cycle influence on lymph-node involvement, receptor status, postoperative metastatic spread and local recurrence . Ann Oncol. 2:1991;269-272.
31. Sigurdsson H, Baldertorp B, Borg A. Timing of surgery in the menstrual cycle does not appear to be a significant determinant of outcome in primary breast cancer. Proc ASCO. 11A:1993;73.
32. Nathan B, Bates T, Anbazhagan R. Timing of surgery for breast cancer in relation to the menstrual cycle and survival of premenopausal women. Br J Surg. 80:1993;43.
33. Donegan W, Shah D. Prognosis of patients with breast cancer related to the timing of operation. Arch Surg. 128:1993;309-313.
34. Wobbes T, Thomas C, Segers M. The phase of menstrual cycle has no influence on the disease-free survival of patients with mammary carcinoma. Br J Cancer. 69:1994;599-600.
35. Kroman N, Hojgaard A, Andersen K. Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Eur J Surg Oncol. 20:1994;430-435.
36. Corder A, Cross M, Julios S. The timing of breast cancer within the menstrual cycle. Postgrad Med J. 70:1994;281-284.
37. Jaeger W, Sauerbrei W. Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Breast Cancer Res Treat. 34:1995;279-287.
38. Low S, Galea M, Blamey R. Timing breast cancer surgery. Lancet. 338:1991;691.
39. Garcia-Gonde J, Lluch A, Cervantes A. Timing of surgery during menstrual cycle does not influence prognosis in breast cancer patients. Proc Ann Meet Am Soc Clin Oncol. 11:1992;56.
40. Grant F, Seifert M, Jakesz R. Breast cancer and timing of surgery during menstrual cycle a 5-year analysis of 385 pre-menopausal women . Int J Cancer. 52:1992;707-712.
41. Sauerbrei W, Bastert G, Schmoor C. Prognostic effect of timing of surgery during menstrual cycle in premenopausal breast-cancer patients. Int J Cancer. 59:1994;149-150.
42. D'Eredita G, De Leo G, Punzo C. Timing of breast cancer surgery during menstrual cycle a 10-year analysis of 133 premenopausal women . The Breast. 4:1995;25-28.
43. Weimer DA, Donegan WL. Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle. Breast Cancer Res Treat. 10:1987;273-278.
44. Senie R, Kinne D. Menstrual timing of treatment for breast cancer. Monogr Natl Cancer Inst. 16:1994;85-90.
45. Randal J. Does the timing of breast cancer surgery affect survival? J Natl Cancer Inst. 87:(7):1997;473-477.
46. Hrushesky W. Breast cancer, timing of surgery, and the menstrual cycle call for prospective trial . J Women's Health. 5:(6):1996;555-565.
47. Larsen WS. Optimal timing of breast cancer surgery. Findings revive debate. J Natl Cancer Inst. 85:(8):1993;605-607.
48. McGuire W. The optimal timing of mastectomy low tide or high tide? Intern Med. 115:1991;401-403.
49. Gruber SA, Nichol KL, Sothern RB, et al. Menstrual history and breast cancer. Breast Cancer Res Treat. 13:1989;278.
50. Fentiman I, Gregory W, Richards M. Effects of menstrual phase on surgical treatment of breast cancer. Lancet. 344:1994;402.
51. Hrushesky W. Menstrual cycle timing of breast cancer resection: prospective study is overdue. J Nat Cancer Inst 1995;87(2):143. [Letter to the editor].
52. Ehrlich P, Apolant H. Beobachtungen (Uber maligne Mausetumoren. J M Res. 28:1905;309-322.
53. Ehrlich P. Referat uber die genese des carcinoms. Verhandl d deutsch path Gesselsch. 12:1908;13-32.
54. Apolant H. The question of immunity. J Exp Med. 14:1911;316.
55. Marie P, Clunet J. Frequence de metastases viscerales chez les souris cancereuses apres ablation chirurgicale de leur tumeur. Bull Assoc Franc P L'etude du Cancer. 3:1910;19-23.
56. Tyzzer E. Factors in production and growth of tumor metastases. J Med Res. 28:1913;309-322.
57. Simpson-Herron L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 60:1976;1749-1760.
58. Lloyd C. The ovaries. Williams R. Textbook of Endocrinology. 4th ed. 1968;459-536 WB Saunders, Philadelphia.
59. Hotchkiss J, Knobil E. The menstrual cycle and its neuroendocrine control. Knobil E, Neill J. The Physiology of Reproduction. Vol 2:1993;711-750 Raven Press, New York.
60. Badwe R, Fentiman I, Saad Z, et al. Surgical procedures, menstrual cycle phase, and prognosis in operable breast cancer. Lancet 1991;338:815-816. [Letter to the editor].
61. Bariozzari T, Leonhardt J, Wiltrout RH, et al. Direct evidence for the role of LGL in the inhibition of experimental tumor metastasis. J Immunol. 134:1985;2783-2789.
62. Wiltrout RH, Herberman RB, Zhang SR. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol. 134:1985;4267-4275.
63. Hanna N, Scheider M. Enhancement of tumor metastasis and suppression of natural killer cell activity of β-estradiol treatment. J Immunol. 130:1982;974-980.
64. Pollock RE, Babcock GF, Romsdahl M, Nishioka K. Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Cancer Res. 44:1984;3888-3891.
65. Pollock RE, Lotzova E, Stanford SD. Effect of surgical stress on murine natural killer cell cytotoxicity. J Immunol. 138:1987;171-178.
66. Hrushesky WJM, Gruber SA, Sothern RB, et al. Natural killer cell activity age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential . J Natl Cancer Inst. 80:1988;1232-1237.
67. Torossov MT, Hrushesky WJM, Gupta H, et al. Fertility cycle dependent tumor growth on-linearity unmasked. Proc Am Assoc Cancer Res. 36:1995;38.
68. Krzanowski M. Low human T4:T8 lymphocyte ratios around ovulation time. Chronobiologia. 12:1985;254.
69. CO human breast cancer cells by progestins implications for endocrine therapies . Cancer Res. 45:1985;167-173.
70. Butler W, Kirkland W, Jorgensen T. Induction of plasminogen activator in human breast cancer cell line (MCF-7). Biochem Biophys Res Commun. 90:1979;1228-1334.
71. Westley B, Rochefort H. Estradiol induced protein in MCF-7 human breast cancer cell line. Biochem Biophys Res Commun. 90:1979;410-416.
72. Goldfarb R. Proteolytic enzymes in tumor invasion and degradation of host extracellular matrices. Mech Cancer Metast 341-375.
73. Thorpe S, Rochefort H, Garcia M. Association between increased concentrations of Mr 52,000 cathepsin D and poor prognosis in human breast cancer. Cancer Res. 49:1989;6008-6014.
74. Zajchowski D, Sager R. Induction of estrogen related genes differs in immortal and tumorigenic human mammary epithel cells expressing a recombinant estrogen receptor. Mol Endocrinol. 5:1991;1613-1623.
75. Jarvis P, Kutten F, Gompi A. Estrogen and progesterone interaction in normal and pathologic breast cells. Ann NY Acad Sci USA. 464:1980;152-167.
76. Loeffler G, Petrides P. Tumorgewebe. Physiologische Chemie. 1989;975 Springer Verlag, Berlin.
77. Van der Burg B, Ruttemann G, Blankenstein M. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium synergistic action of insulin and estrogen . J Cell Physiol. 134:1988;101-108.
78. Yee D, Cullen K, Paik S. Insulin like growth factor II mRNA expression in human breast cancer. Cancer Res. 48:1988;6691-6696.
79. Steward A, Johnson M, May F. Role of insulin-like growth factor receptor in estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 265:1990;21172-21178.
80. Chrousos G. The hypothalamic-pituitary-adrenal axis and the immune-mediated inflammation. NEJM. 332:1995;1351-1362.
81. Anderson T, Battersky S, King RJB, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol. 20:1989;1139-1144.
82. Longacre T, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Pathol. 255:1986;58-61.
83. Silva JS, Georgiade GS, Dilley WG, et al. Menstrual cycle-dependent variations of breast cyst fluid proteins and sex steroid receptors in the normal human breast. Cancer. 51:1983;1297-1302.
84. Pollow K, Schmidt-Goldwitzer M, Nevinny-Stickel J. Progesterone receptors in normal human endometrium and endometrial carcinoma. McGuire W, Paynaud JP, Baulieu EE. Progesterone Receptors in Normal and Neoplastic Tissues. 1977;313-338 Raven Press, New York.
85. Heise E, Gorlich M. Estradiol receptor in human breast cancers throughout the menstrual cycle. Oncology. 39:1982;340-344.
86. Saez S, Martin PM, Chouvet CD. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res. 38:1978;3468-3473.
87. Coradini D, Cappelletti V, Miodini P, et al. Variations in estrogen and progesterone receptor content in premenopausal breast cancer patients throughout the menstrual cycle. Tumori. 70:1984;339-344.
88. Smyth CM, Benn DE, Reeve TS. Influence of the menstrual cycle on the concentrations of estrogen and progesterone receptors in primary breast cancer biopsies. Breast Cancer Res Treat. 11:1988;45-50.
89. Battersby S, Robertson B, King R, McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer. 65:1992;601-607.
90. Folkman JM, Long D, Becker FF. Growth and metastasis of tumor in organ culture. Cancer. 16:1963;453-467.
91. Kim KJ, Bing L, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844.
92. Schweike D, Hin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth hormone (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 91:1991;2235-2243.
93. Iruela-Arispe M, Porter P, Bornstein P, Sage E. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest. 97:1996;403-412.
94. Pratt D, Miller W, Dawes J. Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol. 25:1989;343-350.
95. Irwin J, Kirk D, Gwatkin BL, et al. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. J Clin Invest. 97:1996;438-447.
96. Ayus J, Wheeler J, Arieff A. Postoperative hypoatremic encephalopathy in enstruant women. Ann Intern Med. 117:1992;891-897.
97. Roof R, Duvdevani R, Stein DG. Gender influences outcome of brain injury progesterone plays a protective role . Brain Res. 607:1993;333-335.
98. Roof R, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Rest Neurol Neurosci. 4:1992;425-427.
99. Liotta L, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34:1974;997-1004.
100. Zacharski LR, Moritz TE, Baczek LA, et al. Effect of mopidamole on survival in carcinoma of the lung and colon final report of Veterans Administration Cooperative Study No. 188 . J Natl Cancer Inst. 80:1988;90-97.
101. Orchard M, Botting JH. The influence of sex hormones on rat platelet sensitivity to adenosine-diphosphate. Thrombos Haemostas. 46:1981;496.
102. Rosen S, Berk M, Popp D, et al. B2- and A2-adrenergic receptors and receptor coupling to adenylate cyclase in human mononuclear leukocytes and platelets in relation to physiological variations of sex steroids. J Clin Endocrinol Metab. 58:1984;1068-1076.
103. Yamazaki H, Motomiya T, Kikutani N, et al. Platelet aggregation during the menstrual cycle and pregnancy. Thromb Res. 14:(2)(3):1979;333-340.
104. Solerte S, Fioravanti M, Spinillo A, et al. Association between hormonal and haemorheological changes during the menstrual cycle in healthy women. Br J Obstet Gynecol. 95:1988;1305-1308.
105. Fisher B, Fisher ER. Experimental evidence in support of the dormant tumor cell. Science. 130:1959;918-919.
106. Fisher BGN, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49:1989;1996-2001.
107. Gnant F, Seifert M, Jakesz R. Breast cancer and timing of surgery during menstrual cycle a 5-year analysis of 385 pre-menopausal women . Int J Cancer. 52:1992;707-712.